Pfizer/Eisai's Aricept high dose 'should not have been approved' say US doctors
This article was originally published in Scrip
Executive Summary
Doctors in the US are calling for the US FDA to write "drug boxes" for inclusion within product labelling after raising concerns over the regulator's 2010 decision to approve the highest strength (23mg) of Pfizer and Eisai's Alzheimer's disease treatment, Aricept (donepezil), an acetylcholinesterase inhibitor.